RCM
CLDX icon

RA Capital Management’s Celldex Therapeutics CLDX Stock Holding History

RA Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,734,972
Closed -$62.4M – 55
2023
Q1 		$62.4M Sell
1,734,972
-340,028
-16% -$14.7M 1.41% 24
2022
Q4 		$92.5M Hold
2,075,000
– – 1.88% 20
2022
Q3 		$58.3M Hold
2,075,000
– – 1.24% 29
2022
Q2 		$55.9M Hold
2,075,000
– – 1.49% 19
2022
Q1 		$70.7M Buy
2,075,000
+270,205
+15% +$8.64M 1.54% 16
2021
Q4 		$69.7M Buy
1,804,795
+204,795
+13% +$8.92M 1.23% 21
2021
Q3 		$86.4M Buy
+1,600,000
New +$75.1M 1.2% 27
2020
Q4 		– Sell
-353,072
Closed -$5.24M – 83
2020
Q3 		$5.24M Sell
353,072
-796,928
-69% -$9.34M 0.1% 65
2020
Q2 		$14.9M Buy
+1,150,000
New +$5.1M 0.29% 45

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

RA Capital Management's CLDX Position: Q2 2023 in Review

RA Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2023, closing a stake of 1,734,972 shares — an estimated $62.4M sold.

RA Capital Management first reported a position in CLDX in Q2 2020 and held it in 9 quarters. The position peaked at $92.5M in Q4 2022. 150 funds tracked by Wall St. Rank hold CLDX as of Q2 2023.

  • RA Capital Management reported no remaining Celldex Therapeutics position as of Q2 2023 after selling out during the quarter.
  • RA Capital Management sold 1,734,972 Celldex Therapeutics shares in Q2 2023, an estimated $62.4M.
  • RA Capital Management first reported a position in Celldex Therapeutics in Q2 2020 and held it in 9 quarters.
  • RA Capital Management's Celldex Therapeutics position peaked at $92.5M in Q4 2022.
  • 150 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2023.

Based on RA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.